Comment on Sattar et al. Weight Reduction With Tirzepatide Varied Meaningfully by Baseline HbA1c Category in Adults With Overweight or Obesity and Type 2 Diabetes in SURMOUNT-2. Diabetes Care 2025;48:e136–e137

What is it about?

This letter discusses a post hoc analysis from the SURMOUNT-2 trial, suggesting that individuals with higher HbA1c levels lost less weight with tirzepatide. I caution that baseline differences and statistical artefacts may influence such results, and therefore require more rigorous analysis before drawing firm conclusions.

Featured Image